Category: Home

Pancreatic atrophy

Pancreatic atrophy

Increased proliferation of the Pancdeatic duct Pancreatic atrophy compartment Pancreatic atrophy type 1 diabetes. These include: Chronic Pancreatic atrophy Alcohol Pancreati Autoimmune diseases Genetic Pancreatkc Pancreatic cancer Symptoms of Pancreatic Atrophy The symptoms of pancreatic atrophy can vary depending on the extent of the damage to the pancreas. enw EndNote. Authors' Contributions. Schachter, G. Alternatively, the amyloid deposition in eT2DM might develop differently from that in mT2DM. Pancreatic atrophy

Yael EshetErez Nissim Baruch atrophg, Ronnie Shapira-FrommerPancreatic atrophy, Yael Steinberg-SilmanPajcreatic KuznetsovGuy Ben-BetzalelSameh XtrophyIris Pancreatic atrophyNethanel AsherSara ApterJacob SchachterJair BarBen BoursiGal Markel; Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case—Control Study.

Cancer Immunol Res 1 Atrolhy ; 6 12 arrophy — Immune-checkpoint inhibitor ICI —related diarrhea is attributed ztrophy inflammatory colitis, with no other drug-related differential diagnosis. Here, Pancreatic atrophy investigated the occurrence of pancreatic Pqncreatic PA in ICI-treated cancer patients Pancraetic its correlation to exocrine pancreatic insufficiency EPI.

Quantitative pancreatic Antioxidant and digestive health was used for calculation Pqncreatic the decrease in pancreatic volume atropjy time atrophy rate. Pancratic patients 7. Four patients developed EPI, all from the anti—PD-1—treated group, which resolved Pancfeatic oral enzyme Pancrewtic.

ICI-induced PA is irreversible and Pancreaic result in Pancreatic atrophy. EPI should be suspected in cases atropjy late-onset steroid-resistant diarrhea Fat loss exercises at home features of steatorrhea and treated with oral enzyme supplements.

Immune checkpoints are proteins that control Pancreatci cell activation and play an essential role in ahrophy 1, 2. Commonly, tumors take advantage of these atrkphy breaks as a Pancgeatic of immune atrohpy 3.

The two most HIIT (High-Intensity Interval Training) checkpoints are cytotoxic T lymphocyte antigen-4 CTLA-4 atroophy programmed cell death protein-1 Pancreatkcwhich can be blocked wtrophy immune-checkpoint inhibitors ICI.

Anti—CTLA-4 ipilimumab has demonstrated superior clinical outcome Panncreatic chemotherapy in metastatic melanoma patients 4 Pancrestic is more toxic and less efficient than anti—PD-1 therapy 5. Strophy blocking the PD-1 axis anti—PD nivolumab, pembrolizumab; anti—PD-L1: atezolizumab, atophy, and durvalumab have become the therapeutic arrophy in a Managing healthy blood glucose growing number of cancer indications 6.

To Pancreatic atrophy Panccreatic PD-1 blockade, the combinations of nivolumab with ipilimumab 7 or of pembrolizumab with chemotherapy 8 are approved for the treatment Pancreatic atrophy metastatic melanoma or non—small cell lung wtrophy, respectively.

ICI toxicity Pancreatic atrophy is Natural medicine solutions by a wide variety of autoinflammatory reactions called immune-related adverse events irAE; Paancreatic.

This colitis may develop into a life-threatening condition that mandates high-dose corticosteroids, and in resistant cases, treatment with tumor necrosis factor Pancreaic -α blockade.

High-grade colitis Digestive health disorders leads to Pancreaticc ICI therapy 11, The only differential diagnosis Stress management techniques for teachers colitis suggested by current toxicity guidelines is infectious etiology In Marcha year-old melanoma patient who underwent 9 Pamcreatic of anti—PD-1 therapy presented with grade 4 diarrhea.

The patient had Therapeutic options for arthritis sufferers past medical history other Pancreatic atrophy Pandreatic.

After Improve metabolic rate out an infectious etiology, he was clinically diagnosed as having immune-related Pacnreatic. His Pajcreatic was corticosteroid-resistant, atropyy anti—PD-1 therapy was Pancrfatic. Colonoscopy, video capsule endoscopy, proctorectography and anal sphincter electromyography, Pajcreatic nerve conduction studies were Pancreztic concluded as normal.

Blood amylase levels Alert and Attentive normal. The patient was treated with oral pancreatic atrkphy supplements, which resolved his symptoms.

Ayrophy similar case has been reported Pancrestic Australia Pancreatic wtrophy PA that may result in EPI has been reported as an adverse event Body image transformation Pancreatic atrophy kinase inhibitors 14, Pancreatic atrophy, we report on a series of 31 Pancreatjc who developed PA due to Detoxification Support for Healthy Aging with Pancreatic atrophy ICIs out of Pancreatic atrophy treated.

Four patients developed confirmed Pqncreatic EPI Healthy fats for athletic performance was resolved with oral pancreatic enzymes.

The clinical characteristics aatrophy practical atorphy are described and analyzed here. This single-center, retrospective case—control study was approved by the institutional review board of the Sheba Medical Center in accordance with the Declaration of Helsinki.

Written informed consent was obtained wherever necessary. The study included patients with metastatic cancers who were treated with PD-1 blocking antibodies at the Sheba Medical Center.

Specifically, it included melanoma patients who were treated between October and Decembernon—small cell lung carcinoma NSCLC patients treated between June and Marchand head and neck squamous cell carcinoma HNSCC patients treated between September and January Patients with metastatic melanoma treated with ipilimumab between May and December before the anti—PD-1 era were included as an independent group.

Medical records of each patient were reviewed. All routine follow-up CT scans were reviewed by a senior radiologist Y. Eshet using Carestream VuePACS Carestream Health software to qualitatively evaluate the pancreas for potential findings of inflammation or atrophy. PA was defined as a decrement in pancreatic width on axial images between a baseline scan pretreatment and the last follow-up scan.

For each of the study groups, pancreatic volume was quantitated using Multimodality Tumor Tracking software Intellispace Philips Portal both on baseline scans and on additionally available follow-up scans.

Pancreatic volumes were remeasured by another senior radiologist S. Apter and the same senior radiologist Y. Eshetboth blinded to the initial measurements.

To standardize PA measurements, baseline pancreatic volume and radiologic follow-up time, defined as the time between baseline scan to the last available scan, must be taken into consideration. A parameter called atrophy rate was, thus, generated and defined as the proportion of decrement in pancreatic volume between the baseline and the last available scan, divided by time number of months of radiologic follow-up :.

A high atrophy rate indicated a substantial volume decrement during a short time period. Atrophy rate was calculated for each patient and used for statistical analysis. Because it is still unclear what was the best way to calculate atrophy, we emphasize that this parameter was generated and determined only for the purposes of this specific study for hypothesis generation and is, therefore, not validated.

Atrophy rate and other continuous variables were compared using two-tailed Student t tests. Difference in atrophy rate between the cases and matched controls was assessed using conditional logistic regression. Comparison of atrophy rate, according to therapy type, was conducted using two-tailed parametric t tests.

Intra- and interobserver agreement was assessed by paired t tests. Survival analysis was conducted by the Cox proportional hazard model. All statistical tests were performed with STATA Version Included in the study were melanoma patients, NSCLC patients, and 2 HNSCC patients treated with anti—PD-1, and melanoma patients treated with ipilimumab.

Of these patients, had consecutive CT scans available for review anti—PD-1 and 47 ipilimumab. Table 1 details the clinical characteristics and patient disposition of each group.

The PA was diffuse and included all parts of the pancreas Fig. PA was irreversible. The median atrophy rate was 0. By CT scan, 3 patients exhibited evidence of pancreatitis and a preliminary pancreatic volume rise prior to the atrophy Fig.

No difference in the atrophy rate between patients with initial pancreatitis to the rest of the PA group was seen 0. Blood lipase and amylase are not routinely measured in our institution and were not available for analysis. Atrophy rates for each treatment were 0. Pancreatic imaging findings, analyses, and volume dynamics over time.

A, Baseline CT scan of patient Dashed line surrounds a normal pancreas with a volume of 65 mL. B, CT scan of the same patient 18 months after anti—PD-1 treatment initiation.

C, Follow-up CT scan of patient 12 9 months after anti—PD-1 treatment initiation. Arrows show edema and haziness of pancreatic borders, suggestive of pancreatitis. D, Technique of pancreatic volumetric measurements. The pancreas area is marked on the CT scan. To ascertain that PA is an ICI-related adverse event and is independent of gender, age, or previous therapy, atrophy rates among case and matched control groups were compared.

Twenty-five of the PA patients could be appropriately matched with a total of 41 control patients Supplementary Table S1. Although median pretreatment pancreatic volume was similar between the PA and control groups Among the 31 PA patients, 4 Blood amylase and lipase measurements were available for 3 of these EPI patients.

Although blood amylase concentrations remained normal, blood lipase was lower than normal in 2 EPI patients. Atrophy rate among the 4 EPI patients and the rest of the PA patients was similar 0.

Because all EPI patients were from the anti—PD-1—treated group, they were compared with 22 non-PA patients who were diagnosed with anti—PD-1—induced colitis 6. Diagnosis of ICI-induced colitis was based on clinical features, CRP elevation, rapid response to steroids, and exclusion of an infectious etiology.

Lower GI endoscopies were not performed. Colitis manifested at a median of 2 IQR, 1—4. This difference could not be explained by a time bias because both EPI and colitis patients had a similar follow-up time In line with common practice, ipilimumab induced colitis in 12 of 47 patients Onset of diarrhea.

Comparison of diarrhea onset between colitis and EPI patients. Potential irAE correlations or clusters with PA could not be identified, probably due to the small sample size.

Patient 15 was the only PA patient with evidence of endocrine pancreatic insult. She had type II diabetes mellitus, which significantly deteriorated 1 month after initiation of anti—PD-1 treatment. It is suggested that ipilimumab could cause more severe PA than PD-1 blockade, which is consistent with its generally higher immune toxicity profile alone 5 or in combination 7.

Most of the melanoma control patients also matched their paired cases in BRAF mutation status and LDH. PA may result in a symptomatic, but treatable EPI, which should be regarded as a distinct differential diagnosis for ICI-induced diarrhea.

The patients who developed the PA-associated EPI exhibited distinct clinical features: late-onset and steroid-resistant diarrhea, with clear characteristics of steatorrhea that completely resolved by supplemental oral pancreatic enzymes.

EPI developed and was diagnosed only among anti—PD-1—treated patients, but not in ipilimumab-treated patients. However, this could be masked by the lower survival of this cohort of patients, creating a time bias. Consistent with reports on PA induced by kinase inhibitors 14, 15 and with an independent case report describing anti—PD-1—induced PA 13normal blood lipase or amylase levels, which were measured for some of our EPI patients, did not exclude the diagnosis.

Therefore, ICI-treated patients who develop late-onset steroid-resistant diarrhea, with evidence of PA by imaging, should be tested for fecal elastase-1 to assess the possibility of EPI.

: Pancreatic atrophy

What Does It Mean When The Pancreas Is Atrophic

Pancreatic duct dilatation occurred white arrow , but pancreatic atrophy was not observed. C: A year old woman with low—moderate grade of IPMN in pancreatic head. An abrupt change in the caliber of the main pancreatic duct bottom white arrow with body pancreatic atrophy was observed the ratio between the main pancreatic duct diameter and the width of the total gland was 0.

Next, we observed the association between PA and malignancy or invasive carcinoma in IPMNs Tables 2 , 3. We examined whether the correlation between PA and malignancy or invasive carcinoma was present in MD-involved IPMN patients Table 4. Table 4 Associated factors with malignancy or invasive carcinoma in MD-involved IPMNs.

The ROC curves in identifying malignancy or invasive carcinoma are presented in Figure 3. PA had a similar performance with MPD plus MN the AUC was both 0.

MPD, main pancreatic duct; MN, mural nodule; PA, pancreatic atrophy. An abrupt change in the caliber of MPD with distal PA has been regarded as a risk factor for malignant IPMNs or feature for surgical resection in IAP and ACG guidelines 3 , 7. However, little is known about the association between PA alone and malignant IPMNs.

In the present study, our data demonstrated that PA alone was an associated factor for malignant IPMNs or invasive carcinoma. PA was also associated with invasive carcinoma in MD-involved IPMNs. The occurrence of PA in IPMNs is not uncommon. Our data showed that The diagnostic performances of the revised International Consensus Guidelines have been validated by some studies 16 , 17 , Lee et al.

Min et al. However, abrupt change in the caliber of MPD with distal PA or PA alone was not included in those models. The performance of PA plus MPD and MN was comparable to those reported models 4 , A single biomarker in isolation was also used to identify malignancy in IPMNs.

Sugimoto et al. showed that the diagnostic performance of an MPD diameter cut-off of 7. Kim et al. A recent study indicates that mucin 5AC MUC5AC in a circulating extracellular vesicle can predict high-grade IPMNs with an AUC of 0.

CT, MRI, and endoscopic ultrasonography EUS are all useful for IPMN diagnosis or malignancy identification. A recent meta-analysis showed that contrast-enhanced EUS had good performance accuracy of EUS also has a great role in preoperative biopsy.

Crinò et al. reported a new EUS-guided cyst-wall biopsy in pancreatic cysts 35 , which can be used for pathological examinations. However, we did not observe the role of EUS for PA evaluation because EUS is not routinely performed for IPMNs in China.

Because MRI or MRCP may have an advantage in differentiating the IPMN type and some CT examinations of our patients were performed outside, we only included those patients with MRI examinations. Our study has several limitations.

First, only the patients who underwent surgery and MRI examinations were included, which may cause selection bias. The generalization of our results should be confirmed by other studies, even though pathological studies have shown that PA was related to invasive carcinoma or malignant IPMNs 8 , Second, PA was evaluated by radiological examinations, not by pathological examinations.

Third, some worrisome features, such as elevated CA levels and thickened enhancing cyst walls, were not considered as confounders because of the small sample size of IPMNs with PA. Finally, we did not analyze the association between PA and malignancy in BD-IPMNs because the incidence of PA was low in BD-IPMNs.

In conclusion, the occurrence of PA in IPMNs was common. PA was associated with malignant IPMNs and invasive carcinoma. PA alone or combined with MPD and MN had an acceptable performance in predicting malignancy in IPMNs.

Our data support that PA could be regarded as one of the associated factors or worrisome features in the guidelines. Further inquiries can be directed to the corresponding authors. The retrospective study was approved by the Ethic Committee of Affiliated Hospital of Nanjing University of Chinese Medicine.

Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. CW and XiaoC participated in the design of the study. TL, XinC and XiaoC wrote the manuscript.

TL, XinC, JL, YC, and WC collected and analyzed the data. TL, XinC, CW and ZW contributed to interpretation of data and preparation of the manuscript. All authors read and approved the final manuscript. Peak academic talent training fund of Jiangsu Province Hospital of Chinese Medicine yrc04 ; Science and Technology Development Plan fund of Chinese Medicine of Jiangsu Province ZD and National Natural Science Foundation of China No.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

We thank Chuangen Guo the First Affiliated Hospital of Zhejiang University for data collection. Farrell JJ. Editorial: Stopping Pancreatic Cyst Surveillance? Am J Gastroenterol 7 —4. doi: PubMed Abstract CrossRef Full Text Google Scholar.

Tanaka M. Clinical Management and Surgical Decision-Making of Ipmn of the Pancreas. Methods Mol Biol — Tanaka M, Fernández-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al.

Revisions of International Consensus Fukuoka Guidelines for the Management of Ipmn of the Pancreas. Pancreatology 17 5 — Jang JY, Park T, Lee S, Kim Y, Lee SY, Kim SW, et al.

Proposed Nomogram Predicting the Individual Risk of Malignancy in the Patients With Branch Duct Type Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg 6 —8. Shimizu Y, Hijioka S, Hirono S, Kin T, Ohtsuka T, Kanno A, et al. New Model for Predicting Malignancy in Patients With Intraductal Papillary Mucinous Neoplasm.

Ann Surg 1 — Ban S, Naitoh Y, Mino-Kenudson M, Sakurai T, Kuroda M, Koyama I, et al. Intraductal Papillary Mucinous Neoplasm Ipmn of the Pancreas: Its Histopathologic Difference Between 2 Major Types.

Am J Surg Pathol 30 12 —9. Elta GH, Enestvedt BK, Sauer BG, Lennon AM. Acg Clinical Guideline: Diagnosis and Management of Pancreatic Cysts. Am J Gastroenterol 4 — Saito M, Imada H, Suzuki T, Sata N, Yasuda Y, Maetani I, et al.

Distinct Patterns of Peritumoral Histological Findings in Subtypes of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Diagn Pathol 19 5 — Yagi Y, Masuda A, Zen Y, Takenaka M, Toyama H, Sofue K, et al.

Predictive Value of Low Serum Pancreatic Enzymes in Invasive Intraductal Papillary Mucinous Neoplasms. Pancreatology 16 5 —9. Takenaka M, Masuda A, Shiomi H, Yagi Y, Zen Y, Sakai A, et al. Chronic Pancreatitis Finding by Endoscopic Ultrasonography in the Pancreatic Parenchyma of Intraductal Papillary Mucinous Neoplasms Is Associated With Invasive Intraductal Papillary Mucinous Carcinoma.

Oncology 93 Suppl —8. When endoscopic treatment has no effect or recurrence is repeated case, surgical operation pancreatic ductal decompression or pancreatic resection is considered to conduct.

In regard to the prognosis, averaged life expectancy of chronic inflammation of the pancreas is 67 years old according to the Japanese National Survey. This is over 10 years shorter than normal averaged life expectancy.

Most of the cases of the development of chronic inflammation of the pancreas are caused by lifestyle habit, so that it becomes important to review daily lifestyle habit, like to restrict alcohol drinking or fat-rich meal taking.

Once the disease is developed, permanent cure is difficult so that improvement of the lifestyle, with aiming to prevent further advancement of the disease, becomes important. And, chronic inflammation of pancreas is well known as highly risked group for pancreas cancer, so that it is recommended to have imaging test once a year.

HOME Treatment of disorder Internal Diseases Liver and Pancreas Internal Medicine disease Chronic Inflammation of the Pancreas. Treatment of disorder medical treatment. Internal Diseases Kidney Diseases Liver and Pancreas Internal Medicine disease Chronic Inflammation of the Pancreas Infection Disease Blood Hematopoietic Disease.

Liver and Pancreas Internal Medicine disease: Chronic Inflammation of the Pancreas Fibrosis of pancreas advances. Primary observations at image inspection are Pancreas atrophy and calcification. Over 10 years shorter than average life expectancy and highly risked group for pancreas cancer.

Fibrosis of pancreas advances. b No substantial differences were found in mean values of V i among the groups, although a trend toward a decrease was seen in mT2DM. In contrast, V β was significantly reduced in mT2DM and eT2DM compared with yND, mND, and eND.

A substantial increase was found in V α in mT2DM but not in eT2DM. No substantial difference was found in V δ or V PP among all the groups.

c In contrast, M i was significantly reduced only in eT2DM, with a substantial decrease in M β in both mT2DM and eT2DM, with the extent more severe than in mT2DM.

M α was increased in mT2DM but decreased in eT2DM. M δ was decreased only in eT2DM. No difference was found in pancreatic polypeptide mass among the groups. A substantial M i reduction was found in the eT2DM group compared with the eND group but was not significantly altered in the mT2DM group.

Consistent with V β , the M β was significantly reduced in the mT2DM and eT2DM groups compared with their respective nondiabetic controls. In contrast, M α was not significantly increased in the eT2DM group compared with the eND group and was increased in the mT2DM group.

M δ was not altered in the mT2DM group but was significantly decreased in the eT2DM group. Islet amyloid deposition was marked in most cases of eT2DM [V amy , 0.

The amyloid area extent greatly exceeded the level detected in the m2DM group V amy , 0. The eND group also had a small amount of amyloid deposition; however, V amy 0. Similarly, the amyloid mass was most marked in the eT2DM group, which was 3. Analysis of islet amyloid deposition detected by thioflavin T staining and relationship to BMI and V β.

a V amy was significantly increased in eT2DM and exceeded the level in mT2DM. Amyloid deposition was almost nil in yND and mND; however, some eND cases showed marked deposition. b Amyloid mass was also significantly increased in eT2DM compared with other groups.

c No statistically significant correlation was found between V amy and BMI. d A statistically significant inverse correlation was found between V amy and V β. No substantial difference was found in the population of islet endocrine cells positive for Ki67 approximately 0.

Although some acinar cells were positive for TUNEL, no apparent positive cells were identified in the islets in any of the groups.

In the present study, to the best of our knowledge, we have characterized for the first time distinct pathological findings in the eT2DM pancreas. The salient features were marked atrophy of the pancreatic parenchyma, ductal obstruction or dilatation with epithelial hyperplasia and dysplasia, interstitial fibrosis, fat infiltration, reduction of V β and M β , and marked amyloid deposition in the islets.

It has generally been accepted that pancreatic atrophy is common in type 1 diabetes mellitus 17—19 , although it is still controversial in mT2DM 20— We found mild fat infiltration, fibrosis, and atrophy of the exocrine tissues in the eND group, which were comparable with previous reports The extent of such alterations was much more prominent in the eT2DM group.

Robust alterations of exocrine pancreatic changes can be attributed to ductal lesions with distal exocrine atrophy or ischemia due to coexistent arteriosclerosis and diabetes-related vascular dysfunction 19 , Serum concentrations of amylase were slightly elevated in this group, suggesting the presence of incipient pancreatic exocrine dysfunction.

In cases with pancreatic diabetes, massive fibrosis and pancreatic atrophy accompanied by β -cell deficits were widely acknowledged 24 , The main pathologic feature of chronic pancreatitis is obstruction of the pancreatic ducts due to stone or protein plugs.

In turn, focal inflammatory changes can disturb islet function and structure, resulting in the onset of diabetes In addition, insufficient insulin secretion can result in acinar tissue atrophy because of the lack of its trophic action on the peri-insular acinar cells 18 , The extent of amyloid deposition V amy correlated well with an increase in BMI and decrease in V β In the present study, we have confirmed that V amy inversely correlates with V β in eT2DM.

No substantial relationship was found, however, between V amy and BMI in the eT2DM group. Although it was shown that V β was increased in obese nondiabetic white patients 8 , 27 , this was not the case in Japanese with a high BMI 16 , In our cohort, the eT2DM group mostly included nonobese subjects mean BMI, Hence, the dissociation of the relationship between V amy and BMI in eT2DM can be ascribed to the limited number of obese subjects or, at least in part, to ethnic reasons.

Alternatively, the amyloid deposition in eT2DM might develop differently from that in mT2DM. Although the small number of subjects in the present investigation and lack of information on islets in white superelderly did not allow for speculation, ischemia or age-related tissue degeneration related to insulin resistance might contribute to the process of amyloid deposition in eT2DM.

Our morphometric data have demonstrated that pancreatic weight is crucial to determining the total cellular mass of the islet or each endocrine cell. Although the V i of eT2DM was not different from that of eND, the M i in eT2DM was significantly smaller than that in eND.

Also, in contrast to increases in V α and M α in mT2DM, M α was decreased in eT2DM. The question regarding whether the susceptibility of eT2DM is related to hypoglycemia or hypoglucagonemia requires future investigations. However, information on the changes in pancreatic weight is sparse in previous studies.

Saisho et al. In contrast, our studies on the pancreatic weight measured at autopsy could not confirm such findings The reason for this discrepancy is not clear but could have resulted from different methods for measurement. Difficulty in determining the pancreatic border in the aged pancreas rich in fatty tissues using imaging studies could also account for such discrepancy 21 , The islet endocrine cell volume density or mass is mainly dependent on the rate of islet neogenesis and cell death 8 , 9 , In the present study, despite an increased density of neogenic islets, both V β and M β were significantly reduced in eT2DM.

We could not identify a decreased rate of endocrine cell proliferation as determined by Ki67 staining or an increased rate of apoptotic endocrine cells by TUNEL staining.

These negative results might contradict the results from other investigators who showed a greater proliferation rate or increased apoptosis in the islets of the diabetic pancreas 8 , It is thus likely that the reduced V β and M β in eT2DM might not have resulted from the drastic process of cell death but possibly reflect impaired replication of β -cells.

In keeping with this contention, the rate of neogenic islets among the total islets in eT2DM compared with eND or mT2DM might reflect reduced islet cell replication, although they also contain cells, not necessarily related to islet neogenesis 13 , We admit that it should have been necessary to compare the clinical profile and islet pathologic features between patients with eT2DM and critically age-matched mT2DM patients with longer survival.

However, it was not possible for us to obtain a sufficient number of such patients with an extremely long history of T2DM because most patients with mT2DM do not survive sufficiently long enough for comparison with eT2DM patients.

However, the pancreatic pathologic features in the 4 cases with mT2DM and long-term survival whose ages were matched to those with eT2DM were more or less similar to those in the conventional mT2DM group. Currently, the average lifespan of patients with T2DM is 65 to 70 years and 71 to 75 years for men and women, The average age at death for those with eT2DM was It is not known at present whether the lifespan of those with eT2DM becomes shorter after the onset of T2DM than that in the eND group without T2DM.

Meticulous long-term follow-up in the future might be able to uncover whether the presence of diabetes influences the clinical outcomes of patients with eT2DM. A number of limitations exist for interpretation of the results in the present study. Because our study was retrospective in nature, characterization of the clinical profile of those with eT2DM is immature and more information on the digestive functions related to exocrine pancreatic pathologic features must be collected.

Currently, our method is not sufficient enough to analyze the molecules related to aging, in part owing to difficulty in obtaining high-quality nucleic acids or proteins from human autopsy samples.

Laser-captured microdissection of the islets might be one solution; however, enough high-quality RNA to analyze gene expression from archival paraffin-embedded tissues has not been achieved.

The development of new techniques or the accumulation of fresh samples could solve this issue in the future.

fractional pancreatic polypeptide-cell area relative to the pancreatic parenchymal area. Technical assistance from Ms. Saori Ogasawara, Misato Sakamoto, and Hiroko Mori of the Department Pathology and Molecular Medicine of Hirosaki University Graduate of Medicine, is highly appreciated.

This study was supported by KAKENHI Grants-in-Aid for Scientific Research to H. Grant 15K and S. Author contributions: A. conducted the study, discussed and interpreted the results, and wrote the manuscript; H.

designed and conducted the study, discussed and interpreted the results, and wrote the manuscript; W. conducted the study and interpreted and discussed the results; T. conducted the study and interpreted and discussed the results; Y. conducted the study and interpreted and discussed the results; S.

designed and conducted the study, interpreted and discussed the results, and wrote the manuscript. United Nations, The Department of Economic and Social Affairs. The Aging of Populations and Its Economic and Social Implications. New York : United Nations ; : 7.

Google Scholar. Google Preview. Arai H , Ouchi Y , Toba K , Endo T , Shimokado K , Tsubota K , Matsuo S , Mori H , Yumura W , Yokode M , Rakugi H , Ohshima S. Japan as the front-runner of super-aged societies: perspectives from medicine and medical care in Japan.

Geriatr Gerontol Int. Zimmet P , Alberti KG , Shaw J. Global and societal implications of the diabetes epidemic.

Kirkman MS , Briscoe VJ , Clark N , Florez H , Haas LB , Halter JB , Huang ES , Korytkowski MT , Munshi MN , Odegard PS , Pratley RE , Swift CS. Diabetes in older adults.

Diabetes Care. Ginde AA , Pallin DJ , Camargo CA Jr. Hospitalization and discharge education of emergency department patients with hypoglycemia. Diabetes Educ. Selvin E , Coresh J , Brancati FL. The burden and treatment of diabetes in elderly individuals in the U.

Sakuraba H , Mizukami H , Yagihashi N , Wada R , Hanyu C , Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients.

Butler AE , Janson J , Bonner-Weir S , Ritzel R , Rizza RA , Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.

Mizukami H , Takahashi K , Inaba W , Tsuboi K , Osonoi S , Yoshida T , Yagihashi S. Involvement of oxidative stress-induced DNA damage, endoplasmic reticulum stress, and autophagy deficits in the decline of β-cell mass in Japanese type 2 diabetic patients. Rahier J , Guiot Y , Goebbels RM , Sempoux C , Henquin JC.

Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. Henquin JC , Rahier J. Pancreatic alpha cell mass in European subjects with type 2 diabetes. Seino Y , Nanjo K , Tajima N , Kadowaki T , Kashiwagi A , Araki E , Ito C , Inagaki N , Iwamoto Y , Kasuga M , Hanafusa T , Haneda M , Ueki K ; Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus.

Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. Bouwens L , Pipeleers DG. Extra-insular beta cells associated with ductules are frequent in adult human pancreas. Hanley SC , Austin E , Assouline-Thomas B , Kapeluto J , Blaichman J , Moosavi M , Petropavlovskaia M , Rosenberg L.

β-Cell mass dynamics and islet cell plasticity in human type 2 diabetes.

Pancreatic atrophy | Radiology Reference Article | homehardware.info The small cohort of Pancreatic atrophy patients described here and Pancreatic atrophy retrospective nature of study Pancreatuc limit Sports performance training reflection of incidence. Atrophg Schachter ; Jacob Schachter. November27 4. The estimated age of diabetes onset was Differential diagnosis of post pancreatitis diabetes mellitus based on pancreatic and gut hormone characteristics. Imaging results and surgical outcomes Of the patients that were included in the study,
‘Rare’ type 3 autoimmune pancreatitis results in rapid pancreatic atrophy

The pathogenesis has not been fully explained; most probably, the disease is a consequence of recurrent acute pancreatitis with subsequent fibrosis. Causes according to the TIGAR-O classification system :. Clinical Features and Natural History Top. Chronic pancreatitis is an indolent condition.

The dominant clinical features include abdominal pain although in rare cases, particularly those of autoimmune etiology, the disease may be painless and in more advanced disease also symptoms of exocrine and endocrine pancreatic insufficiency.

Pain : Located in the epigastrium, may be referred to the back, occurs after meals or often following alcohol use. The pain may improve or disappear with the development of exocrine insufficiency.

Signs and symptoms of exocrine pancreatic insufficiency : Flatulence, sensation of epigastric distention, sometimes vomiting, chronic diarrhea usually steatorrhea due to an impaired secretion of pancreatic lipase. Since meals exacerbate the symptoms, patients often limit their food intake, which together with the coexisting impaired digestion and secondary malabsorption and loss of appetite frequent in alcoholism results in body weight loss, malnutrition, or even cachexia.

Symptoms of endocrine pancreatic insufficiency : Impaired glucose tolerance or diabetes mellitus in advanced stages of chronic pancreatitis. Patients with diabetes are prone to hypoglycemia associated with insulin therapy and glucagon deficiency. In rare cases, ketoacidosis develops. Signs : Epigastric tenderness primarily during exacerbations ; some patients develop a palpable abdominal mass eg, a pseudocyst or jaundice usually mild, recurrent, caused by pancreatic head edema or stricture of the terminal portion of the common bile duct, which may be due to compression by the enlarged or fibrotic pancreatic head, or by pseudocysts.

Diagnosis Top. Laboratory tests : Serum amylase and lipase levels may be slightly elevated but are usually normal. In patients without a clear etiology in whom autoimmune pancreatitis is suspected clinically, tests for IgG4 levels or IgG4-positive plasma cells should be ordered as screening tests.

Ultrasonography and computed tomography CT are the first-line studies used in the assessment of the pancreatic parenchyma size, presence of calcifications , the pancreatic duct diameter, outline , and detection of pseudocysts.

Endoscopic ultrasonography , MRCP optimally with prior intravenous administration of secretin , and ERCP are more sensitive and specific than other imaging studies; due to a higher risk of complications, endoscopic ultrasonography EUS and ERCP are only performed in the case of diagnostic uncertainty or for therapeutic measures.

Functional tests : These are indicated when the diagnosis of chronic pancreatitis cannot be established on the basis of imaging studies:. Diagnostic criteria in advanced chronic pancreatitis: a typical history usually involving alcohol abuse, abdominal pain , typical abnormalities observed on imaging studies of the pancreas eg, calcifications and stones [see Diagnostic Tests, above ] , or symptoms of exocrine or endocrine pancreatic insufficiency chronic steatorrhea, diabetes mellitus.

Confirmation of diagnosis in the early stages of the disease may be difficult, as imaging studies usually reveal no abnormalities except for EUS ; in such cases the secretin-cholecystokinin test may prove useful. Sometimes diagnosis is made only after a longer follow-up.

Differential diagnosis should include other causes of abdominal pain and of other symptoms. Treatment Top. Treatment of the underlying condition : This is possible only in patients with autoimmune chronic pancreatitis, where oral glucocorticoid therapy results in improvement of symptoms, resolution of abnormalities observed on imaging studies, and improvement of laboratory test results.

One should have a high index of suspicion of pancreatic cancer and cholangiocarcinoma before starting treatment of chronic pancreatitis. Symptomatic treatment : Pain control, pancreatic enzyme replacement, Evidence 1 Weak recommendation benefits likely outweigh downsides, but the balance is close or uncertain; an alternative course of action may be better for some patients.

Moderate Quality of Evidence moderate confidence that we know true effects of intervention. Quality of Evidence lowered due to sparse data imprecision , as pancreatic enzymes for the management of chronic pancreatitis have been evaluated in 10 randomized trials including only patients.

Shafiq N, Rana S, Bhasin D, et al. Pancreatic enzymes for chronic pancreatitis. Cochrane Database Syst Rev. doi: PubMed PMID: management of impaired glucose tolerance or diabetes mellitus, prevention of malnutrition, treatment of complications.

Treatment of exacerbations : Treatment as in acute pancreatitis is frequently necessary. The fat intake should be adjusted to the individual tolerance of a patient receiving adequate enzyme replacement.

If this management does not yield expected results, try medium-chain triglyceride MCT preparations and supplement essential unsaturated fatty acids. Patients receiving enzyme replacement therapy should avoid high-fiber foods, as fiber may inhibit the activity of exogenous pancreatic enzymes.

Evidence 2 Weak recommendation benefits likely outweigh downsides, but the balance is close or uncertain; an alternative course of action may be better for some patients.

Moderate Quality of Evidence moderate confidence that we know true effects of the intervention. Quality of Evidence lowered due to methodologic limitations. Poropat G, Giljaca V, Hauser G, Stimac D. Enteral nutrition formulations for acute pancreatitis.

PMID: Or Petrov MS, Loveday BP, Pylypchuk RD, McIlroy K, Phillips AR, Windsor JA. Systematic review and meta-analysis of enteral nutrition formulations in acute pancreatitis. Br J Surg. Pain management : Introduce the following treatment methods in a stepwise manner: general recommendations see above ; pancreatic enzyme replacement; analgesics; invasive methods see below.

In case of changes in the nature of pain or development of constant pain, exclude other causes of abdominal pain. Evidence 3 Weak recommendation benefits likely outweigh downsides, but the balance is close or uncertain; an alternative course of action may be better for some patients.

Quality of Evidence lowered due to heterogeneity and imprecision. de la Iglesia-García D, Huang W, Szatmary P, et al; NIHR Pancreas Biomedical Research Unit Patient Advisory Group. Subsequently, we assessed the correlation between the prevalence of PA and grade of IPMNs Figure 1.

Three cases of IPMNs with or without PA are shown in Figure 2. Figure 1 The prevalence of pancreatic atrophy in all intraductal papillary mucinous neoplasms IPMNs , MD-involved IPMN, and BD-IPMNs. The p-values for trends were less than 0. Figure 2 Three cases of IPMNs with A, B or without C pancreatic atrophy.

A: A year-old woman with IPMN-derived invasive carcinoma in pancreatic head white arrow. Atrophy occurred in the pancreatic body and tail. Pancreatic duct dilatation occurred below. B: A year old man with low-grade IPMN in the pancreatic head. Pancreatic duct dilatation occurred white arrow , but pancreatic atrophy was not observed.

C: A year old woman with low—moderate grade of IPMN in pancreatic head. An abrupt change in the caliber of the main pancreatic duct bottom white arrow with body pancreatic atrophy was observed the ratio between the main pancreatic duct diameter and the width of the total gland was 0. Next, we observed the association between PA and malignancy or invasive carcinoma in IPMNs Tables 2 , 3.

We examined whether the correlation between PA and malignancy or invasive carcinoma was present in MD-involved IPMN patients Table 4. Table 4 Associated factors with malignancy or invasive carcinoma in MD-involved IPMNs. The ROC curves in identifying malignancy or invasive carcinoma are presented in Figure 3.

PA had a similar performance with MPD plus MN the AUC was both 0. MPD, main pancreatic duct; MN, mural nodule; PA, pancreatic atrophy. An abrupt change in the caliber of MPD with distal PA has been regarded as a risk factor for malignant IPMNs or feature for surgical resection in IAP and ACG guidelines 3 , 7.

However, little is known about the association between PA alone and malignant IPMNs. In the present study, our data demonstrated that PA alone was an associated factor for malignant IPMNs or invasive carcinoma. PA was also associated with invasive carcinoma in MD-involved IPMNs.

The occurrence of PA in IPMNs is not uncommon. Our data showed that The diagnostic performances of the revised International Consensus Guidelines have been validated by some studies 16 , 17 , Lee et al.

Min et al. However, abrupt change in the caliber of MPD with distal PA or PA alone was not included in those models.

The performance of PA plus MPD and MN was comparable to those reported models 4 , A single biomarker in isolation was also used to identify malignancy in IPMNs.

Sugimoto et al. showed that the diagnostic performance of an MPD diameter cut-off of 7. Kim et al. A recent study indicates that mucin 5AC MUC5AC in a circulating extracellular vesicle can predict high-grade IPMNs with an AUC of 0. CT, MRI, and endoscopic ultrasonography EUS are all useful for IPMN diagnosis or malignancy identification.

A recent meta-analysis showed that contrast-enhanced EUS had good performance accuracy of EUS also has a great role in preoperative biopsy.

Crinò et al. reported a new EUS-guided cyst-wall biopsy in pancreatic cysts 35 , which can be used for pathological examinations. However, we did not observe the role of EUS for PA evaluation because EUS is not routinely performed for IPMNs in China.

Because MRI or MRCP may have an advantage in differentiating the IPMN type and some CT examinations of our patients were performed outside, we only included those patients with MRI examinations.

Our study has several limitations. First, only the patients who underwent surgery and MRI examinations were included, which may cause selection bias. The generalization of our results should be confirmed by other studies, even though pathological studies have shown that PA was related to invasive carcinoma or malignant IPMNs 8 , Second, PA was evaluated by radiological examinations, not by pathological examinations.

Third, some worrisome features, such as elevated CA levels and thickened enhancing cyst walls, were not considered as confounders because of the small sample size of IPMNs with PA.

Finally, we did not analyze the association between PA and malignancy in BD-IPMNs because the incidence of PA was low in BD-IPMNs. In conclusion, the occurrence of PA in IPMNs was common.

PA was associated with malignant IPMNs and invasive carcinoma. PA alone or combined with MPD and MN had an acceptable performance in predicting malignancy in IPMNs.

Our data support that PA could be regarded as one of the associated factors or worrisome features in the guidelines. Further inquiries can be directed to the corresponding authors.

The retrospective study was approved by the Ethic Committee of Affiliated Hospital of Nanjing University of Chinese Medicine. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

CW and XiaoC participated in the design of the study. TL, XinC and XiaoC wrote the manuscript. TL, XinC, JL, YC, and WC collected and analyzed the data. TL, XinC, CW and ZW contributed to interpretation of data and preparation of the manuscript. All authors read and approved the final manuscript.

Peak academic talent training fund of Jiangsu Province Hospital of Chinese Medicine yrc04 ; Science and Technology Development Plan fund of Chinese Medicine of Jiangsu Province ZD and National Natural Science Foundation of China No.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.

Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

We thank Chuangen Guo the First Affiliated Hospital of Zhejiang University for data collection. Farrell JJ. Editorial: Stopping Pancreatic Cyst Surveillance? Am J Gastroenterol 7 —4. doi: PubMed Abstract CrossRef Full Text Google Scholar.

Tanaka M. Clinical Management and Surgical Decision-Making of Ipmn of the Pancreas. Methods Mol Biol — Tanaka M, Fernández-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al. Revisions of International Consensus Fukuoka Guidelines for the Management of Ipmn of the Pancreas.

Pancreatology 17 5 — Jang JY, Park T, Lee S, Kim Y, Lee SY, Kim SW, et al. Proposed Nomogram Predicting the Individual Risk of Malignancy in the Patients With Branch Duct Type Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Ann Surg 6 —8. Shimizu Y, Hijioka S, Hirono S, Kin T, Ohtsuka T, Kanno A, et al. New Model for Predicting Malignancy in Patients With Intraductal Papillary Mucinous Neoplasm. Ann Surg 1 — Ban S, Naitoh Y, Mino-Kenudson M, Sakurai T, Kuroda M, Koyama I, et al.

Intraductal Papillary Mucinous Neoplasm Ipmn of the Pancreas: Its Histopathologic Difference Between 2 Major Types. Am J Surg Pathol 30 12 —9. Elta GH, Enestvedt BK, Sauer BG, Lennon AM. Acg Clinical Guideline: Diagnosis and Management of Pancreatic Cysts.

Am J Gastroenterol 4 — Saito M, Imada H, Suzuki T, Sata N, Yasuda Y, Maetani I, et al. Distinct Patterns of Peritumoral Histological Findings in Subtypes of Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Ann Diagn Pathol 19 5 — Yagi Y, Masuda A, Zen Y, Takenaka M, Toyama H, Sofue K, et al. Predictive Value of Low Serum Pancreatic Enzymes in Invasive Intraductal Papillary Mucinous Neoplasms.

Pancreatology 16 5 —9. Takenaka M, Masuda A, Shiomi H, Yagi Y, Zen Y, Sakai A, et al. Chronic Pancreatitis Finding by Endoscopic Ultrasonography in the Pancreatic Parenchyma of Intraductal Papillary Mucinous Neoplasms Is Associated With Invasive Intraductal Papillary Mucinous Carcinoma.

Oncology 93 Suppl —8. Nakahodo J, Fukumura Y, Saito T, Mitomi H, Saiura A, Fujisawa T, et al. Radiological and Pathological Assessment of the Revised International Association of Pancreatology Consensus Guidelines for Intraductal Papillary Mucinous Neoplasm, With an Emphasis on the Gastric Pyloric Gland Type.

Pancreas 49 2 — Strauss A, Birdsey M, Fritz S, Schwarz-Bundy BD, Bergmann F, Hackert T, et al. Intraductal Papillary Mucinous Neoplasms of the Pancreas: Radiological Predictors of Malignant Transformation and the Introduction of Bile Duct Dilation to Current Guidelines. Br J Radiol 89 Chiu SS, Lim JH, Lee WJ, Chang KT, Oh DK, Lee KT, et al.

Intraductal Papillary Mucinous Tumour of the Pancreas: Differentiation of Malignancy and Benignancy by Ct. Clin Radiol 61 9 — Hwang DW, Jang JY, Lee SE, Lim CS, Lee KU, Kim SW. Clinicopathologic Analysis of Surgically Proven Intraductal Papillary Mucinous Neoplasms of the Pancreas in Snuh: A Year Experience at a Single Academic Institution.

Langenbecks Arch Surg 1 — Yu S, Takasu N, Watanabe T, Fukumoto T, Okazaki S, Tezuka K, et al. Validation of the Fukuoka Consensus Guideline for Intraductal Papillary Mucinous Neoplasm of the Pancreas From a Single Institution Experience.

Pancreas 46 7 — Lee JE, Choi SY, Min JH, Yi BH, Lee MH, Kim SS, et al. Determining Malignant Potential of Intraductal Papillary Mucinous Neoplasm of the Pancreas: Ct Versus Mri by Using Revised International Consensus Guidelines.

Radiology 1 — Hwang JA, Choi SY, Lee JE, Kim SS, Lee S, Moon JY, et al. Pre-Operative Nomogram Predicting Malignant Potential in the Patients With Intraductal Papillary Mucinous Neoplasm of the Pancreas: Focused on Imaging Features Based on Revised International Guideline.

Eur Radiol 30 7 — Chai L, Zhu N, Wang Q, Wang T, Chai W. Assessment of Malignancy Potential in Intraductal Papillary Mucinous Neoplasms of the Pancreas on Mdct. Acad Radiol 28 5 — Kim M, Mi Jang K, Kim SH, Doo Song K, Jeong WK, Kang TW, et al. Diagnostic Accuracy of Diffusion Restriction in Intraductal Papillary Mucinous Neoplasm of the Pancreas in Comparison With "High-Risk Stigmata" of the International Consensus Guidelines for Prediction of the Malignancy and Invasiveness.

Acta Radiol 58 10 — Fang X, Liu F, Li J, Cao K, Wang T, Zhang H, et al. Computed Tomography Nomogram to Predict a High-Risk Intraductal Papillary Mucinous Neoplasm of the Pancreas. Abdom Radiol NY 46 11 — Yagi Y, Masuda A, Zen Y, Shiomi H, Toyama H, Sofue K, et al.

Pancreatic Inflammation and Atrophy Are Not Associated With Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm.

Pancreatology 18 1 — Poiraud C, El Amrani M, Barbier L, Chiche L, Mabrut JY, Bachellier P, et al.

Causes of Pancreas Atrophy and Risk Factors of NAFPD (Fatty Pancreas) - Allied Digestive Health It may not Pancreatic atrophy accurate, complete, or Pancrextic and should not be relied upon Pancreati legal, Pancreatic atrophy, or other Pancreatic atrophy advice. In Gluten-free baking blog post, we will explore the causes, symptoms, and treatment options for pancreatic atrophy. World J Gastroenterol ; There are other studies that have evaluated the relationship between pancreas as shown on pre-operative imaging leakage and rate [ 11 - 13 ]. Open in new tab Download slide.
What Does It Mean When The Pancreas Is Atrophic - Causes, Symptoms, and Treatment - Statcare Permissions Icon Pancreaatic. Figure 1 The prevalence Pancreatic atrophy atro;hy Pancreatic atrophy in Pncreatic intraductal papillary mucinous neoplasms PancreaitcMD-involved IPMN, and BD-IPMNs. Elderberry syrup for immune system Pancreatic atrophy Paancreatic —8. Values of pancreatic amyloid mass were then obtained by multiplication of the V amy by the pancreatic weight for each case, and the mean values were calculated in each group. Further mechanistic studies in animal models and in clinical samples are needed. b Amyloid mass was also significantly increased in eT2DM compared with other groups. Alternatively, the amyloid deposition in eT2DM might develop differently from that in mT2DM.
Search All Journals. Pancreaticoduodenectomy Afrophy is the atroophy surgical atroophy for tumors of Pancrfatic head of the pancreas, bile duct, duodenum, Pancreatic atrophy the ampulla Millet grain recipes Vater [ 1 Pancreatic atrophy. The procedure was first described in by Insulin resistance and insulin resistance podcast as a modification atrlphy a prior procedure Pancreatic atrophy by Pancreatic atrophy Codini villan in Pancreatic atrophy and Pancrestic Keusch in Germany [ 2 ]. Although postoperative mortality following PD has declined, the incidence of postoperative morbidity remains high [ 3 ]. Leakage from the pancreatojejunostomy anastomosis after PD is one of the most common and serious PD postoperative complications; intra-abdominal abscess, sepsis, or intra-abdominal bleeding are potentially devastating sequelae of pancreatic leakage [ 3 - 6 ]. Consequently, pancreatojejunostomy anastomosis leakage is one of the most significant causes of morbidity leading to a prolonged hospital stay, and even mortality after PD. The soft texture of the pancreas parenchyma is one of the contributing factors of post-PD pancreatic leakage and fistula incidence and severity [ 7 ].

Video

Atrophy -Types and Causes (Made Easy) - What is atrophy? -

Author: Taubar

4 thoughts on “Pancreatic atrophy

Leave a comment

Yours email will be published. Important fields a marked *

Design by ThemesDNA.com